

FROM FERRING PHARMACEUTICALS:

Endometrin[®]

(progesterone) Vaginal Insert 100mg



Now available for optimal luteal support in ART¹⁻⁴

- Rapidly dissolving, soy-based, micronized progesterone inserts created specifically for vaginal administration
- No generic available
- Dosing¹
 - BID (morning and at bedtime)
 - TID (morning, dinnertime, and at bedtime)
- Each individually sealed insert comes with its own individually wrapped applicator¹
- Patient-friendly product answers unmet market need vs other progesterone options^{1,4}
- Over 1,000,000 inserts prescribed since June 2007 introduction²

Ordering Information

DESCRIPTION	STRENGTH	FORM	CONTENTS	NDC#	WAC	CIN
ENDOMETRIN [®]	100 mg	Tablet-like insert	Box of 21 inserts, 21 applicators	55566-6500-03	\$109.62	3991791



(Applicator and Insert Shown Actual Size)

Endometrin[®]

(progesterone) Vaginal Insert 100mg



ENDOMETRIN[®] administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN[®]. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2% included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2%. ENDOMETRIN[®] is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness).

REFERENCES: 1. ENDOMETRIN [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; June 2007. 2. Data on File. Ferring Pharmaceuticals Inc. 3. Doody KJ, Schnell VL, Foulk RA, et al. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. *Fertil Steril*. 2008;In press. 4. Progesterone Therapy: The Patient Perspective. Results of an Online Patient Survey. New York, NY: The American Fertility Association (AFA); 2007.

Please see accompanying full Prescribing Information.